Genomic Health, Inc. (GHDX) Insider Sells $349,900.00 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $34.99, for a total transaction of $349,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kimberly J. Popovits also recently made the following trade(s):

  • On Thursday, December 14th, Kimberly J. Popovits sold 20,000 shares of Genomic Health stock. The shares were sold at an average price of $31.50, for a total transaction of $630,000.00.

Genomic Health, Inc. (NASDAQ GHDX) opened at $33.88 on Friday. Genomic Health, Inc. has a 52-week low of $26.37 and a 52-week high of $37.50. The company has a market cap of $1,178.52, a P/E ratio of -282.33 and a beta of 0.66.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Wednesday, November 8th. The medical research company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. Genomic Health had a negative net margin of 1.30% and a negative return on equity of 1.79%. equities analysts expect that Genomic Health, Inc. will post -0.08 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Genomic Health by 6.8% during the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock valued at $54,379,000 after acquiring an additional 106,452 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Genomic Health by 10.9% in the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after purchasing an additional 80,100 shares during the last quarter. State Street Corp grew its holdings in shares of Genomic Health by 2.5% in the second quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock worth $16,840,000 after purchasing an additional 12,696 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Genomic Health by 1.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 503,244 shares of the medical research company’s stock worth $16,150,000 after purchasing an additional 5,904 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Genomic Health by 26.1% in the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after purchasing an additional 76,758 shares during the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

GHDX has been the topic of a number of recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $42.00 target price on shares of Genomic Health in a research note on Tuesday, January 16th. Jefferies Group reaffirmed a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a research note on Friday, October 20th. Zacks Investment Research upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, ValuEngine upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $32.33.

COPYRIGHT VIOLATION WARNING: “Genomic Health, Inc. (GHDX) Insider Sells $349,900.00 in Stock” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/21/genomic-health-inc-ghdx-insider-sells-349900-00-in-stock.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply